Association of Apolipoprotein C3 Levels and Hepatic Steatosis: A Follow-Up Study

Abstract Apolipoprotein C3 is a lipid-binding protein with a pivotal role in triglyceride metabolism and inflammation. This 11-year follow-up study aimed to evaluate apolipoprotein C3 levels and other parameters as markers of hepatic steatosis, in a random, population-based cohort in southern Germany. In 2013, we selected and re-examined 406 study participants (193 women, 213 men; average age 58.1±11.3 years) from the original “Echinococcus multilocularis and other internal diseases in Leutkirch I“ (EMIL I) cohort studied in 2002. All participants received upper abdominal sonography to grade potential hepatic steatosis, and blood tests to determine apolipoprotein C3 levels and other laboratory parameters. Body mass index, waist-to-hip ratio, and anthropometric measures were documented. The follow-up study conducted in 2013 included a partial correlation analysis. We found an association between hepatic steatosis and elevated apolipoprotein C3 levels (p<0.0001). Study participants with a novel diagnosis of hepatic steatosis had the highest apolipoprotein C3 serum levels (p=0.0002). Hepatic steatosis was associated with low levels of high density lipoprotein cholesterol (p=0.0374), high levels of total cholesterol (p=0.0117), increased homeostasis model assessment of insulin resistance (p=0.0002), elevated alanine transaminase (p<0.0001), elevated aspartate transaminase (p=0.0003), and elevated C-reactive protein (p=0.0446). Apolipoprotein C3 serum levels were associated with the presence, disease grade, and new development of hepatic steatosis likewise to biomarkers of the metabolic syndrome.

[1]  M. Kostapanos,et al.  Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art? , 2019, Expert opinion on pharmacotherapy.

[2]  R. Fan,et al.  Association between body mass index and fatty liver risk: A dose-response analysis , 2018, Scientific Reports.

[3]  H. Burdett Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia , 2016, Annals of clinical biochemistry.

[4]  D. Gaudet,et al.  Targeting APOC3 in the familial chylomicronemia syndrome. , 2014, The New England journal of medicine.

[5]  A. Munshi,et al.  Apolipoprotein C3 gene polymorphisms in Southern Indian patients with nonalcoholic fatty liver disease , 2014, Indian Journal of Gastroenterology.

[6]  Minrui Li,et al.  Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. , 2014, World journal of gastroenterology.

[7]  K. R. Rao,et al.  Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study. , 2014, World journal of hepatology.

[8]  Y. Xin,et al.  Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. , 2014, World journal of gastroenterology.

[9]  D. Gaudet,et al.  AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE , 2014 .

[10]  M. Taskinen,et al.  A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population , 2013, Obesity.

[11]  H. Makhlouf,et al.  Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.

[12]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[13]  Anoop Misra,et al.  Non-Alcoholic Fatty Liver Disease Is Closely Associated with Sub-Clinical Inflammation: A Case-Control Study on Asian Indians in North India , 2013, PloS one.

[14]  A. Hofman,et al.  Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. , 2012, Journal of hepatology.

[15]  R. Hegele,et al.  Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia , 2012, Journal of internal medicine.

[16]  N. Lundbom,et al.  Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease , 2012, Journal of gastroenterology and hepatology.

[17]  R. Aggarwal,et al.  APOC3 and PNPLA3 in non‐alcoholic fatty liver disease: Need to clear the air , 2012, Journal of gastroenterology and hepatology.

[18]  M. Zappa,et al.  The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. , 2011, Journal of hepatology.

[19]  F. Leonetti,et al.  Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans , 2011, Lipids in Health and Disease.

[20]  Jonathan C. Cohen,et al.  Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance , 2011, Hepatology.

[21]  G. Pera,et al.  Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain , 2010, European journal of gastroenterology & hepatology.

[22]  Benjamin M Yeh,et al.  Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? , 2009, Clinical imaging.

[23]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[24]  R. Rector,et al.  Non-alcoholic fatty liver disease and the metabolic syndrome: an update. , 2008, World journal of gastroenterology.

[25]  Y. Nie,et al.  Prevalence of fatty liver disease and its risk factors in the population of South China. , 2007, World journal of gastroenterology.

[26]  Yuichi Harano,et al.  The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reflects the Metabolic Syndrome and Visceral Fat Accumulation , 2007, The American Journal of Gastroenterology.

[27]  G. Bedogni,et al.  Incidence and natural course of fatty liver in the general population: The Dionysos study , 2007, Hepatology.

[28]  H. Nagahara,et al.  Clinical significance of fatty liver associated with metabolic syndrome , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  P. Libby Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. , 2007, Circulation research.

[30]  K. Lindor,et al.  Role of radiologic modalities in the management of non-alcoholic steatohepatitis. , 2007, Clinics in liver disease.

[31]  P. Portincasa,et al.  Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. , 2006, The Journal of nutrition.

[32]  W. Koenig,et al.  Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults , 2006, BMC public health.

[33]  Zamir Halpern,et al.  Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[34]  P. Libby,et al.  Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells , 2006, Circulation.

[35]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[36]  A. Jenkins,et al.  Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. , 2005, Diabetes care.

[37]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[38]  G. Bedogni,et al.  The epidemiology of fatty liver , 2004, European journal of gastroenterology & hepatology.

[39]  Nancy Dekki,et al.  Apolipoprotein CIII promotes Ca2+-dependent β cell death in type 1 diabetes , 2004 .

[40]  H. Kim,et al.  Insulin resistance and C‐reactive protein as independent risk factors for non‐alcoholic fatty liver disease in non‐obese Asian men , 2004, Journal of gastroenterology and hepatology.

[41]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[42]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[43]  G. Assmann,et al.  Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. , 2003, Atherosclerosis.

[44]  N. Wareham,et al.  Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. , 2003, Biochimica et biophysica acta.

[45]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[46]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[47]  M. Bellini,et al.  The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. , 1997, Italian journal of gastroenterology and hepatology.

[48]  A. R. Frisancho Physical Status: The Use and Interpretation of Anthropometry , 1996, The American Journal of Clinical Nutrition.

[49]  T. Goto,et al.  The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[50]  C. Tiribelli,et al.  Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study , 1994, Hepatology.

[51]  A. Pavie,et al.  Doppler echocardiography for the diagnosis of acute cardiac allograft rejection. , 1988, Journal of the American College of Cardiology.

[52]  J. Maxwell,et al.  Ultrasound scanning in the detection of hepatic fibrosis and steatosis. , 1986, British medical journal.

[53]  J. Seilhamer,et al.  Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo CIII genes. , 1984, DNA.

[54]  P. Demacker,et al.  Apolipoprotein C in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia , 1982, Diabetologia.

[55]  W. Brown,et al.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. , 1972, Biochemical and biophysical research communications.

[56]  J. Larosa,et al.  A specific apoprotein activator for lipoprotein lipase. , 1970, Biochemical and biophysical research communications.

[57]  L. N. Valenti,et al.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[58]  C. Konda,et al.  Chylomicronemia syndrome. , 2009, Indian journal of dermatology, venereology and leprology.

[59]  Tetsuji Sato,et al.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. , 2006, Annals of internal medicine.

[60]  H. Jörnvall,et al.  Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[62]  J. McGarry,et al.  Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.

[63]  P. B. Eveleth,et al.  Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee , 1996 .

[64]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[65]  P. Nestel,et al.  Apoprotein C metabolism in man. , 1982, Advances in lipid research.